Equities Analysts Set Expectations for KZR FY2025 Earnings

Kezar Life Sciences, Inc. (NASDAQ:KZR) – Research analysts at William Blair raised their FY2025 EPS estimates for Kezar Life Sciences in a report issued on Thursday, November 13th. William Blair analyst M. Phipps now forecasts that the company will post earnings of ($7.15) per share for the year, up from their previous estimate of ($7.43). William Blair has a “Market Perform” rating on the stock. The consensus estimate for Kezar Life Sciences’ current full-year earnings is ($4.39) per share. William Blair also issued estimates for Kezar Life Sciences’ Q4 2025 earnings at ($1.48) EPS, Q1 2026 earnings at ($1.37) EPS, Q2 2026 earnings at ($1.29) EPS, Q3 2026 earnings at ($1.22) EPS, Q4 2026 earnings at ($1.15) EPS, FY2026 earnings at ($5.03) EPS and FY2027 earnings at ($4.53) EPS.

Several other analysts have also issued reports on the company. TD Cowen lowered Kezar Life Sciences from a “strong-buy” rating to a “strong sell” rating in a research note on Friday, October 17th. Wells Fargo & Company set a $5.00 price objective on shares of Kezar Life Sciences and gave the stock an “equal weight” rating in a report on Friday, October 17th. Jefferies Financial Group cut shares of Kezar Life Sciences from a “buy” rating to a “hold” rating and cut their price objective for the company from $18.00 to $7.00 in a research note on Friday, October 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Kezar Life Sciences in a report on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Kezar Life Sciences to a “sell” rating in a research note on Saturday, September 13th. Four investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Kezar Life Sciences has a consensus rating of “Reduce” and an average price target of $6.00.

Kezar Life Sciences Price Performance

Shares of Kezar Life Sciences stock opened at $6.22 on Monday. The firm has a market capitalization of $45.53 million, a PE ratio of -0.74 and a beta of 0.70. The company has a current ratio of 7.07, a quick ratio of 7.06 and a debt-to-equity ratio of 0.02. Kezar Life Sciences has a 12 month low of $3.53 and a 12 month high of $7.65. The business’s 50-day moving average price is $4.93 and its 200-day moving average price is $4.48.

Kezar Life Sciences (NASDAQ:KZR) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($1.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.81) by $0.28.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Landscape Capital Management L.L.C. bought a new stake in Kezar Life Sciences during the 3rd quarter valued at $51,000. Woodline Partners LP bought a new stake in Kezar Life Sciences in the 1st quarter worth $125,000. Peapod Lane Capital LLC increased its position in shares of Kezar Life Sciences by 9.3% in the third quarter. Peapod Lane Capital LLC now owns 125,773 shares of the company’s stock valued at $491,000 after acquiring an additional 10,650 shares during the period. Stonepine Capital Management LLC increased its position in shares of Kezar Life Sciences by 69.9% in the second quarter. Stonepine Capital Management LLC now owns 169,859 shares of the company’s stock valued at $778,000 after acquiring an additional 69,859 shares during the period. Finally, BML Capital Management LLC raised its stake in shares of Kezar Life Sciences by 738.6% during the first quarter. BML Capital Management LLC now owns 408,138 shares of the company’s stock valued at $1,992,000 after acquiring an additional 359,470 shares during the last quarter. Institutional investors own 67.90% of the company’s stock.

Kezar Life Sciences Company Profile

Kezar Life Sciences, Inc, a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials in lupus nephritis.